Bharat Biotech joins MoU and GCVC to produce Covaxin drug product

Bharat Biotech on May 27 signed a MoU with the Gujarat Covid Vaccine Consortium (GCVC) to contract a drug product Covaxin.

The Gujarat Covid Vaccine Consortium (GCVC) contains Hester Biosciences, the Gujarat Biotechnology Research Center (GBRC), the Gujarat Government and Omnibrx Biotechnologies.

According to the MoU, Bharat Biotech will provide Covaxin drug production technology. The GBRC will act as a consultant and advisor and will facilitate the transfer of technology from Barat Biotech. Hester will provide comprehensive infrastructure to its Gujarat drug manufacturing industry. Omnibrx will serve as a technology support partner.

Also read : Planning to buy Bitcoin on secure routes? Here are your options

The whole process is provided by the Department of Technology, Government of India.

If all goes according to schedule, the drug will be available from August 2021 which will be returned to Bharat Biotech to supplement and complete the vaccine. Heter will invest Rs 40 million in the project.
ShowHester said the proposed production would not affect any predictions or marketing of Hester’s ongoing business, for the 2021-2022 financial year.

Also read : Sebi empowers auditors with audit of listed firms

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top